Rotarix oral suspension in dosing tube. live rotavirus vaccine

Spain
Brand name Rotarix oral suspension in dosing tube. live rotavirus vaccine
Form suspension, oral
Active substance / Dosage
HUMAN ROTAVIRUS · 10 MILLONES GERMENES
Prescription type Prescription Only Medicine
Registration number 05330010
Rotarix oral suspension in dosing tube. live rotavirus vaccine suspension, oral

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Rotarix oral suspension in dosing tube

live antirotavirus vaccine

Read all of this leaflet carefully before your child receives this vaccine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, ask your doctor or pharmacist.
  • This vaccine has been prescribed for your child only, and must not be given to other people.
  • If you notice any adverse reactions, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.

Leaflet contents

  1. What Rotarix is and what it is used for
  2. What you need to know before your child receives Rotarix
  3. How Rotarix is given
  4. Possible side effects
  5. How to store Rotarix
  6. Contents of the pack and other information

1. What Rotarix is and what it is used for

Rotarix is a viral vaccine containing live attenuated human rotaviruses, which helps protect your child from the age of 6 weeks against gastroenteritis (diarrhea and vomiting) caused by rotavirus infection.

How Rotarix works

Rotavirus infection is the most common cause of severe diarrhea in infants and young children. Rotavirus spreads easily through hand-to-mouth contact with the feces of an infected person. Most children with rotavirus diarrhea recover on their own. However, some children become seriously ill with severe vomiting, diarrhea, and fluid loss that can be life-threatening and may require hospitalization.

When administered to a person, the immune system (the body's natural defense) produces antibodies against the types of rotavirus that occur most frequently. These antibodies protect against disease caused by these rotavirus types.

As with all vaccines, Rotarix may not fully protect all vaccinated individuals against rotavirus infections it is intended to prevent.

2. What you need to know before your child receives Rotarix

Rotarix must not be given

  • if your child has previously had an allergic reaction to rotavirus vaccines or to any of the other components of this vaccine (listed in section 6). Signs of an allergic reaction may include itchy skin rash, difficulty breathing, or swelling of the face or tongue.
  • if your child has previously had intussusception (a bowel obstruction in which one segment of the intestine slides into another).
  • if your child was born with an intestinal malformation that could lead to intussusception.
  • if your child has a rare inherited immune system disorder called severe combined immunodeficiency (SCID).
  • if your child has a serious infection with high fever. Vaccination may need to be postponed until recovery. A minor illness, such as a cold, should not prevent vaccination, but inform your doctor first.
  • if your child has diarrhoea or vomiting. Vaccination may need to be postponed until recovery.

Warnings and precautions

Talk to your doctor/healthcare professional before your child receives Rotarix if:

  • your child has close contact with a family member who has a weakened immune system, for example, someone with cancer or who is taking medicines that may weaken their immune system.
  • your child has any gastrointestinal problems.
  • your child has not gained weight or grown as expected.
  • your child has any illness or is taking any medicine that reduces resistance to infection, or if your mother took any medicine during pregnancy that may have weakened the immune system.

If, after receiving Rotarix, your child develops severe stomach pain, persistent vomiting, blood in the stools, a swollen abdomen, and/or high fever, contact a doctor/healthcare professional immediately (see also section 4 “Possible side effects”).

As always, please take care to wash your hands thoroughly after changing used diapers.

Use of Rotarix with other medicines

Inform your doctor if your child is taking or has recently taken any other medicines, or might need to take any, or has recently received any other vaccines.

Rotarix can be given at the same time as other recommended vaccines, such as diphtheria, tetanus, pertussis (whooping cough) vaccine, Haemophilus influenzae type b vaccine, oral or inactivated poliomyelitis vaccine, hepatitis B vaccine, and pneumococcal and meningococcal serogroup C conjugate vaccines.

Use of Rotarix with food and drinks

There are no restrictions on your child eating or drinking, including breastfeeding, before or after vaccination.

Breastfeeding

Based on evidence from clinical trials, breastfeeding does not reduce the protection against rotavirus gastroenteritis provided by Rotarix. Therefore, breastfeeding can be continued during the vaccination period.

Rotarix contains sucrose, glucose, phenylalanine, and sodium

If your doctor has told you that your child has an intolerance to certain sugars, speak with your doctor before your child receives this vaccine.

This vaccine contains 0.15 micrograms of phenylalanine per dose. Phenylalanine may be harmful if your child has phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body cannot eliminate it properly.

This vaccine contains 34 mg of sodium (a main component of table/cooking salt) per dose.

3. How Rotarix is administered

Your child's doctor or nurse will administer the recommended dose of Rotarix. The vaccine (1.5 ml of liquid) is given orally. Under no circumstances should this vaccine be administered by injection.

Your child will receive two doses of the vaccine. Each dose will be given separately, with an interval of at least 4 weeks between doses. The first dose will be administered starting at 6 weeks of age. Both doses of the vaccine should be completed by 24 weeks of age, although they should preferably be given before 16 weeks of age.

Rotarix may be administered to premature infants according to the same vaccination schedule as other newborns, provided that gestation lasted at least 27 weeks.

If your child spits out or regurgitates most of the vaccine dose, a single replacement dose may be administered during the same visit.

When your child receives the first dose of Rotarix, it is recommended that the second dose also be Rotarix (and not another rotavirus vaccine).

It is important to follow the instructions provided by your doctor or nurse regarding follow-up visits. If you missed your scheduled appointment, speak with your doctor.

4. Possible adverse effects

Like all medicines, this vaccine may cause adverse effects, although not everyone experiences them.

The following adverse effects may occur with this vaccine:

  • Frequent (may occur in up to 1 in every 10 doses of the vaccine):

    • diarrhoea
    • irritability
  • Uncommon (may occur in up to 1 in every 100 doses of the vaccine):

    • abdominal pain (see also the following paragraph regarding signs of the very rare adverse effect intussusception)
    • flatulence
    • skin inflammation

Adverse effects reported during the post-marketing use of Rotarix include:

  • Very rare: hives (urticaria)
  • Very rare: intussusception (a part of the intestine becomes blocked or twisted). Signs may include severe stomach pain, persistent vomiting, blood in the stools, swelling of the abdomen and/or high fever. Contact a doctor/healthcare professional immediately if your child experiences any of these symptoms
  • blood in stools
  • in premature infants (born at 28 weeks of gestation or earlier), periods of prolonged breathing pauses may occur more frequently than normal during the first 2-3 days after vaccination
  • children with a rare inherited disorder called severe combined immunodeficiency (SCID) may develop inflammation of the stomach or intestines (gastroenteritis) and may shed the vaccine virus in their stools. Signs of gastroenteritis may include nausea, vomiting, stomach cramps (colic or colicky pains), or diarrhoea

Reporting of adverse effects

If your child experiences any adverse effects, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You may also report them directly through the national reporting system detailed in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Rotarix

Keep this vaccine out of the sight and reach of children.

Do not use this vaccine after the expiry date stated on the container. The expiry date refers to the last day of the month indicated.

Store in a refrigerator (between 2°C and 8°C).

Do not freeze.

Keep in the original packaging to protect from light.

Once opened, the vaccine should be used immediately.

Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging that you no longer need. This will help protect the environment.

6. Contents of the container and other information

Composition of Rotarix

  • The active substance is:

Human rotavirus strain RIX4414 (live, attenuated)*

not less than 106.0 CCID50

  • Produced in Vero cells

  • Other components of Rotarix are: sucrose, disodium adipate, Modified Eagle’s Medium (MEM) (containing phenylalanine, sodium, glucose and other substances), sterile water (see also section 2, “Rotarix contains sucrose, glucose, phenylalanine and sodium”).

Description of the product and package contents

Oral suspension

Rotarix is supplied as a clear, colourless liquid in a single-dose dosing tube (1.5 ml).

Rotarix is available in pack sizes of 1, 10 or 50.

Only certain pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

GlaxoSmithKline Biologicals SA
Rue de l’Institut 89
B-1330 Rixensart
Belgium

For further information regarding this medicinal product, please contact the local representative of the Marketing Authorization Holder:

Belgium/Belgium/Belgium

GlaxoSmithKline Pharmaceuticals SA/NV

Tel/Tel: + 32 10 85 52 00

Lithuania

GlaxoSmithKline Biologicals SA

Tel: +370 80000334

GlaxoSmithKline Biologicals SA

Tel: +359 80018205

Luxembourg/Luxembourg

GlaxoSmithKline Pharmaceuticals SA/NV

Tel/Tel: + 32 10 85 52 00

Czech Republic

GlaxoSmithKline s.r.o.

Tel: + 420 2 22 00 11 11

[email protected]

Hungary

GlaxoSmithKline Biologicals SA

Tel.: +36 80088309

Denmark

GlaxoSmithKline Pharma A/S

Tlf: + 45 36 35 91 00

[email protected]

Malta

GlaxoSmithKline Biologicals SA

Tel: +356 80065004

Germany

GlaxoSmithKline GmbH & Co. KG

Tel: + 49 (0)89 360448701

[email protected]

Netherlands

GlaxoSmithKline BV

Tel: + 31 (0)33 2081100

Estonia

GlaxoSmithKline Biologicals SA

Tel: +372 8002640

Norway

GlaxoSmithKline AS

Tlf: + 47 22 70 20 00

Greece

GlaxoSmithKline Μονοπρόσωπη A.E.B.E

Tel: + 30 210 68 82 100

Austria

GlaxoSmithKline Pharma GmbH.

Tel: + 43 (0)1 97075 0

[email protected]

Spain

GlaxoSmithKline, S.A.

Tel: + 34 900 202 700

[email protected]

Poland

GSK Services Sp. z o.o.

Tel.: + 48 (22) 576 9000

France

Laboratoire GlaxoSmithKline

Tél: + 33 (0) 1 39 17 84 44

[email protected]

Portugal

Smith Kline & French Portuguesa - Produtos

Farmacêuticos, Lda.

Tel: + 351 21 412 95 00

[email protected]

Croatia

GlaxoSmithKline Biologicals SA

Tel.: +385 800787089

Romania

GlaxoSmithKline Biologicals SA

Tel: +40 800672524

Ireland

GlaxoSmithKline (Ireland) Ltd

Tel: + 353 (0)1 4955000

Slovenia

GlaxoSmithKline Biologicals SA

Tel: +386 80688869

Iceland

Vistor hf.

Sími: +354 535 7000

Slovakia

GlaxoSmithKline Biologicals SA

Tel: +421 800500589

Italy

GlaxoSmithKline S.p.A.

Tel:+ 39 (0)45 7741 111

Finland/Finland

GlaxoSmithKline Oy

Puh/Tel: + 358 10 30 30 30

Cyprus

GlaxoSmithKline Biologicals SA

Tel: +357 80070017

Sweden

GlaxoSmithKline AB

Tel: + 46 (0)8 638 93 00

[email protected]

Latvia

GlaxoSmithKline Biologicals SA

Tel: +371 80205045

United Kingdom (Northern Ireland)

GlaxoSmithKline Biologicals SA

Tel: + 44 (0)800 221 441

[email protected]

Date of the most recent review of this leaflet:

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu

This information is intended for healthcare professionals only:

The vaccine is presented as a clear, colourless liquid, free from visible particles, for oral administration.

The vaccine is ready to use (no reconstitution or dissolution required). The vaccine is administered orally and must not be mixed with other vaccines or solutions.

The vaccine should be inspected visually for any foreign particles and/or changes in physical appearance. If any such changes are observed, the vaccine should be discarded.

Disposal of unused vaccines and all materials that have come into contact with them must be carried out in accordance with local regulations.

Instructions for vaccine administration:

Read the instructions for use completely before starting vaccine administration.

What to do before administering Rotarix

  • Check the expiration date.
  • Check that the tube is not damaged or opened.
  • Check that the liquid is clear and colorless, without particles.

Do not use the vaccine if you observe anything abnormal.

  • This vaccine is administered orally directly from the tube.
  • It is ready to use (no need to mix it with anything).

Medical diagram showing components of a device labeled as membrane, tube, tip, and cap on a white background

B Prepare the vial

  1. Remove the cap
    • Keep the cap (required to pierce the membrane).
    • Hold the vial vertically.
  1. Gently tap repeatedly on the top of the vial until all liquid is dislodged
    • Remove all liquid from the narrowest part of the vial by gently tapping just below the membrane.

Technical drawing showing hands removing the protective cap from a medical device with an arrow pointing downward

  1. Place the cap to open the vial
    • Keep the vial held vertically.
    • Hold the vial between your fingers.
    • There is a small protrusion inside the center of the cap's top.
    • Turn the cap upside down (180°).

Technical drawing showing two hands separating a medical device with labels indicating the membrane and the tip of the component

  1. To open the vial
    • Do not twist. Press the cap down to pierce the membrane.
    • Then, lift off the cap.

Two hands holding a vial and a cap, with an arrow indicating to press the cap downward to open it

C Check that the tube has opened correctly

  1. Check that the membrane has been punctured
    • There should be a hole at the top of the tube.
  1. What to do if the membrane has not been punctured
    • If the membrane has not been punctured, return to section B and repeat steps 2, 3, and 4.

Technical diagram showing the

D Administer the vaccine

  • Once the tube has been opened, check that the liquid is clear and free from particles.

Do not use the vaccine if anything abnormal is observed.

  1. Position the child for vaccine administration
    • Sit the child slightly reclined backwards.
  1. Administer the vaccine
    • Carefully administer the liquid to one side of the child's mouth, towards the inside of the cheek.
    • You may need to squeeze the tube several times to deliver the entire content (it does not matter if a drop remains at the tip of the tube).

Black and white drawing of a hand holding a vial to administer medication directly into a newborn's mouth with text in Spanish

Dispose of the empty tube and cap in approved biological waste containers according to local regulations.